Poll

POLL: Will you use biosimilars in your ophthalmic practice?

Author(s):

Sheryl Stevenson

Let us know if you will plan to use biosimilars in your daily practice. The poll will be open until October 10, 2022.

Will you use biosimilars in your ophthalmic practice?

Yes, I plan to use biosimilars in my practice
No, I do not plan to use biosimilars in my practice
Related Videos
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
AAO 2024: Matt Giegengack, MD: Injectable endothelial cell therapy shows promise for improving vision and reducing glare in corneal edema
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
Related Content
USC researchers receive $6 million CIRM grant to advance novel dry AMD therapy
November 21st 2024

USC researchers receive $6 million CIRM grant to advance novel dry AMD therapy

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy
November 19th 2024

Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy

EyePod podcast: Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)
November 1st 2024

Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)

European Commission grants marketing authorization to aflibercept biosimilar from Sandoz Group
November 15th 2024

European Commission grants marketing authorization to aflibercept biosimilar from Sandoz Group

Prevent Blindness declares 5th annual Thyroid Eye Disease Awareness Week
November 15th 2024

Prevent Blindness declares 5th annual Thyroid Eye Disease Awareness Week

© 2024 MJH Life Sciences

All rights reserved.